Next generation of boron neutron capture therapy (BNCT) agents for cancer treatment.

Paolo Coghi, Jinxin Li, Narayan S Hosmane, Yinghuai Zhu

Journal: Medicinal research reviews 2023;43(5):1809-1830

PMID: 37102375

Abstract

Boron neutron capture therapy (BNCT) is one of the most promising treatments among neutron capture therapies due to its long-term clinical application and unequivocally obtained success during clinical trials. Boron drug and neutron play an equivalent crucial role in BNCT. Nevertheless, current clinically used l-boronophenylalanine (BPA) and sodium borocaptate (BSH) suffer from large uptake dose and low blood to tumor selectivity, and that initiated overwhelm screening of next generation of BNCT agents. Various boron agents, such as small molecules and macro/nano-vehicles, have been explored with better success. In this featured article, different types of agents are rationally analyzed and compared, and the feasible targets are shared to present a perspective view for the future of BNCT in cancer treatment. This review aims at summarizing the current knowledge of a variety of boron compounds, reported recently, for the application of BCNT.

© 2023 Wiley Periodicals LLC.

Address: School of Pharmacy, Macau University of Science and Technology, Macau, China.; Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, Illinois, USA.; Sunshine Lake Pharma Co., Ltd., Dongguan, China.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.